A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

This study aims to explore the efficacy and safety of sintilimab combined with SOX versus SOX alone as adjuvant therapy for patients with pIIIC stage or dMMR/MSI-H pIIIA/IIIB stage gastric/gastroesophageal junction adenocarcinoma. A total of 276 subjects are planned to be enrolled in this study. Patients will be randomly assigned in a 1:1 ratio to receive up to 8 cycles of sintilimab combined with SOX or SOX alone as adjuvant therapy.

NCT Number	NCT07492615
Lead Sponsor	Fudan University
Conditions	Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Enrollment	276 participants
Start Date	2026-01-29
Primary Completion	2029-02-20 (estimated)
Study Completion	2033-02-20 (estimated)
Updated on ClinicalTrials.gov	2026-03-25